Stock Price
109.10
Daily Change
-6.52 -5.64%
Monthly
-23.59%
Yearly
60.16%
Q2 Forecast
99.25

Insmed reported $506.24M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
DBV Technologies USD 37.05M 4.06M Sep/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Novartis USD 9.8B 23M Dec/2025
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026